152 related articles for article (PubMed ID: 27452424)
1. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation.
Iulita MF; Ower A; Barone C; Pentz R; Gubert P; Romano C; Cantarella RA; Elia F; Buono S; Recupero M; Romano C; Castellano S; Bosco P; Di Nuovo S; Drago F; Caraci F; Cuello AC
Alzheimers Dement; 2016 Nov; 12(11):1132-1148. PubMed ID: 27452424
[TBL] [Abstract][Full Text] [Related]
2. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
[TBL] [Abstract][Full Text] [Related]
3. Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis.
Iulita MF; Ganesh A; Pentz R; Flores Aguilar L; Gubert P; Ducatenzeiler A; Christie S; Wilcock GK; Cuello AC
J Alzheimers Dis; 2019; 67(1):327-341. PubMed ID: 30636741
[TBL] [Abstract][Full Text] [Related]
4. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
[TBL] [Abstract][Full Text] [Related]
5. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.
Head E; Doran E; Nistor M; Hill M; Schmitt FA; Haier RJ; Lott IT
J Alzheimers Dis; 2011; 23(3):399-409. PubMed ID: 21116050
[TBL] [Abstract][Full Text] [Related]
6. Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome.
Naudé PJ; Dekker AD; Coppus AM; Vermeiren Y; Eisel UL; van Duijn CM; Van Dam D; De Deyn PP
J Alzheimers Dis; 2015; 45(3):733-43. PubMed ID: 25613101
[TBL] [Abstract][Full Text] [Related]
7. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
8. Composite Scores of Plasma Tau and β-Amyloids Correlate with Dementia in Down Syndrome.
Fang WQ; Hwu WL; Chien YH; Yang SY; Chieh JJ; Chang LM; Huang AC; Lee NC; Chiu MJ
ACS Chem Neurosci; 2020 Jan; 11(2):191-196. PubMed ID: 31799825
[TBL] [Abstract][Full Text] [Related]
9. Generation of Rabbit Monoclonal Antibody to Amyloid-β38 (Aβ38): Increased Plasma Aβ38 Levels in Down Syndrome.
Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Miller DL
J Alzheimers Dis; 2015; 46(4):1021-32. PubMed ID: 26402629
[TBL] [Abstract][Full Text] [Related]
10. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
Mehta PD; Capone G; Jewell A; Freedland RL
J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
[TBL] [Abstract][Full Text] [Related]
11. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.
Alhajraf F; Ness D; Hye A; Strydom A
Dev Neurobiol; 2019 Jul; 79(7):684-698. PubMed ID: 31389176
[TBL] [Abstract][Full Text] [Related]
12. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid.
Hanzel CE; Iulita MF; Eyjolfsdottir H; Hjorth E; Schultzberg M; Eriksdotter M; Cuello AC
J Alzheimers Dis; 2014; 40(3):667-78. PubMed ID: 24531161
[TBL] [Abstract][Full Text] [Related]
13. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
[TBL] [Abstract][Full Text] [Related]
14. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.
Schupf N; Zigman WB; Tang MX; Pang D; Mayeux R; Mehta P; Silverman W
Neurology; 2010 Nov; 75(18):1639-44. PubMed ID: 21041786
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
[TBL] [Abstract][Full Text] [Related]
17. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
[TBL] [Abstract][Full Text] [Related]
18. Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome.
Mehta PD; Mehta SP; Fedor B; Patrick BA; Emmerling M; Dalton AJ
Neurosci Lett; 2003 May; 342(3):155-8. PubMed ID: 12757888
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.
Schupf N; Patel B; Silverman W; Zigman WB; Zhong N; Tycko B; Mehta PD; Mayeux R
Neurosci Lett; 2001 Apr; 301(3):199-203. PubMed ID: 11257432
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
